-transparent.png){kind=logo}
Forty-one adult patients with acute myelogenous leukaemia entered remission induced by daunorubicin and cytosine arabinoside, and subsequently received 6 weeks' consolidation therapy with cyclophosphamide plus 6-thioguanine. They were then randomized to either immunotherapy consisting of intradermal BCG plus allogeneic cells or to "no maintenance". Patients receiving immunotherapy had significantly longer remission (P = 0.039) and survival from remission (P = 0.044) as assessed by the log-rank test. The median duration of first remission for 21 patients receiving immunotherapy was 35.14 weeks, compared with 19.71 weeks for 20 patients on no maintenance, and the median survival from remission was doubled in patients receiving immunotherapy. The value of adequate consolidation chemotherapy is confirmed by the comparatively long first remissions in both groups compared with our previous trials, whilst avoidance of maintenance chemotherapy possibly allowed frequent second remissions and similar post-relapse survival in patients from both treatment arms.
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
November 1973,
British journal of cancer,
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
July 1974,
Irish journal of medical science,
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
August 1973,
The British journal of cancer. Supplement,
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
December 1973,
British medical journal,
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
January 1974,
Johns Hopkins medical journal. Supplement,
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
December 1982,
Australian and New Zealand journal of medicine,
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
April 1984,
Lancet (London, England),
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
January 1997,
Journal of internal medicine. Supplement,
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
September 1977,
British journal of haematology,
S R Zuhrie, and
R Harris, and
C B Freeman, and
J E MacIver, and
C G Geary, and
I W Delamore, and
J A Tooth
February 1977,
British journal of haematology,
